Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03075046
Other study ID # CentroAAP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 20, 2017
Est. completion date December 2023

Study information

Verified date June 2023
Source Centro de Atenção ao Assoalho Pélvico
Contact Patrícia Lordêlo, post doc
Phone 5571 988592400
Email pvslordelo@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vulvovaginal candidiasis (CVV) is an infectious process of the female genitourinary tract, an important health issue due to the high incidence and difficulties encountered in the treatment. Therefore, new therapeutic modalities are sought with the capacity to minimize drug side-effects and to reduce recurrent cases. The objective of this stufy is to evaluate the clinical and microbiological response of the 405 nm blue light emitting diode in the treatment of women with vulvovaginal candidiasis and in women with healthy gentourine treatment. A clinical trial was conducted involving 40 women, divided into two groups, the first group consisting of women with a confirmed CVV diagnosis and a second group formed by women with a healthy genitourinary tract, without symptoms and symptoms of the disease. Both groups underwent clinical evaluation and examination with endocervice collection with gynecologist before and after a session of application of the Blue Light Emitting Diode of 405 nm, lasting 4.5 minutes. There will also be an evaluation of the effects of the diary through the questionnaire answered before and after the participants' treatment. It is expected that the 405 nm blue LED will destroy the CVV fungus demonstrated by laboratory examination and also improve the signs and results analyzed by the gynecologist and participants.


Description:

A current treatmente proposal is the use of blue LED of 405 nm wich is a light that has antimicrobial effect when exposed to endogenous porphyrin of the pathogens. This exposition produces reactive oxigen and it causes cells death with no possibilities of resistance by the fungus.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2023
Est. primary completion date February 20, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - women betwen 18 and 65 years old, with clinical suspect of vulvovaginal candidiasis and with health vaginal tract Exclusion Criteria: - Women with pacemakers, with diagnosis and / or suspicion of neoplasias, cognitive deficits, neurological and / or psychiatric diseases, pregnant women and women who have used oral antibiotics, fungicides, corticosteroids and vaginal creams in the last 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Blue LED 405 nm
It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
Other:
Questionnaire of anamnesis
The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist

Locations

Country Name City State
Brazil Centro de Atenção ao Assoalho Pelvico Salvador Ba

Sponsors (3)

Lead Sponsor Collaborator
Centro de Atenção ao Assoalho Pélvico University of Messina, Vitale SG M.D.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Description of types of cells done by oncology and microflora cytology in women treated by blue light emitting diode These exam will be done by the collect of vaginal secretion to analyse types of cells and organisms 15 days
Primary Amount of clue cells quantified by fresh citology in vaginal secretion of women treated by blue light emitting diode These exam will be done by the collect of vaginal secretion using KOH 10% to analyse clue cells by percentage % 5 hours
Primary Value of vaginal pH measurement in women treated by blue light emitting diode These exam will be done by the collect of vaginal secretion using a ph measuring tape to analyse the hydrogen potential in -log10 [aH+] in women treated by blue light emitting diode. It will be used the numeric scale of pH value 30 minutes
Primary Quantification of fungal colony units by the fungus culture in vaginal secretion of women treated by blue light emitting diode These exam will be done by the collect of vaginal secretion using Colony Forming Unit CFU in women treated by blue light emitting diode 15 days
See also
  Status Clinical Trial Phase
Completed NCT02971007 - Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Phase 2
Completed NCT02251093 - Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Phase 3
Completed NCT01293643 - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Phase 3
Not yet recruiting NCT04626258 - Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis Phase 4
Completed NCT02733432 - RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Phase 2
Completed NCT02248506 - Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Phase 4
Completed NCT02730494 - Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Phase 1
Completed NCT02180828 - Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Phase 4
Recruiting NCT04930107 - Vulvovaginal Candidiasis in Canadian Females Early Phase 1
Withdrawn NCT03167957 - Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Phase 2
Recruiting NCT05367089 - The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms Phase 3
Terminated NCT02859493 - Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis N/A
Completed NCT01891331 - A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Phase 2
Completed NCT02888197 - Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization N/A
Completed NCT03975569 - Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis N/A
Recruiting NCT05059145 - A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis Phase 2